Pharmaceuticals
Investor Education Webinar
The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") invites investors to join a webinar with key opinion leaders to discuss a physician's perspective on innova...
2026-03-02 06:56
3172
Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) on WuXi XDC's proprietary WuXiTecan...
2026-02-27 15:00
4523
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself,me...
2026-02-27 08:00
5401
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...
2026-02-27 04:34
6396
ArisGlobal Launches NavaX Translation to Eliminate Manual Translation in Global Pharmacovigilance
Strategic partnership with TransPerfect Life Sciences embeds certified,
pharma-grade translation directly into LifeSphere Safety workflows
BOSTON, Feb. 26, 2026 /PRNewswire/ -- ArisGlobal
2026-02-26 22:12
5288
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
* SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines inEurope to improve vaccine performance and access. * Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic influenza threats. INCHEON, South Korea,...
2026-02-26 21:00
6128
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomi...
2026-02-26 13:54
4416
Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
SHANGHAI, Feb. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio"), a biotech company powered by super-trillion-molecule libraries and AI-driven technologies, today announced the completion of a significant equity restructuring. The shares previously held by Hai...
2026-02-24 22:00
5047
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agree...
2026-02-24 13:14
4203
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. andChina. Concurrently, the company's "AI + Chemical Induction" platform saw its...
2026-02-23 21:00
4706
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Feb. 23, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for exclusive rights to the commercialization of clobetasol propio...
2026-02-23 14:00
4830
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
* Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK. ...
2026-02-23 08:10
5023
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adju...
2026-02-20 07:27
12541
Cambrex Announces Cornell Professor Song Lin as Recipient of the 2025 Snapdragon Prize for Innovation in Chemistry Technology
EAST RUTHERFORD, N.J., Feb. 19, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) and Snapdragon Chemistry, a Cambrex company, are proud to announce that Dr. Song Lin, Tisch University Professor in chemistry and chemical biology at Cornell U...
2026-02-19 19:00
6353
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
Japan's Ministry of Health, Labour and Welfare (MHLW) Approves
PreemieFort® Enteral Solution asPrescription Medicine in the NICU
DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ -- Prolacta Bioscience®
2026-02-19 05:03
5775
Bioiberica Receives Frost & Sullivan's 2025 European New Product Innovation Award for Clinically Validated Native Type II Collagen
The recognition highlights Bioiberica's science-led innovation, clinical
differentiation, and manufacturing excellence in the European innovative
collagen market.
SAN ANTONIO, Feb. 18, 2026 /PRNewswire/ -- Frost & Sullivan
2026-02-18 18:00
6188
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (b...
2026-02-18 05:54
6847
Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
Headlines: * Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1 * Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials su...
2026-02-17 21:00
5691
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)to initiate a Phase II clinical trial inpatients with advanced solid tumors. This marks a significant milestone in the global development of thi...
2026-02-16 08:10
7400
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003
SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, for the treatment of ...
2026-02-14 20:58
10849
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 327 media titles]
2026-03-27 11:15
UFO SIM Launches in Australia, The Ultimate Travel eSIM Starting at Just AU$2/GB
[Picked up by 310 media titles]
2026-04-01 11:03
Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements
[Picked up by 305 media titles]
2026-04-01 09:00
From Doomscroll to Page-Turner: BookXcess Launches The Brain Un-Rot Library to Help Rebuild a Generation's Focus
[Picked up by 301 media titles]
2026-03-31 13:53
DayOne Announces RM28+ Billion Commitment and Talent Initiatives in Malaysia at Inaugural Tech & AI Career Expo
[Picked up by 291 media titles]
2026-04-01 22:23
